¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"vascular permeability factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • stroma factor
    ¹öÆÀÁúÀÎÀÚ, °£ÁúÀÎÀÚ
  • sunprotective factor
    Àϱ¤º¸È£Áö¼ö
  • sebotropic factor
    Áö·çÃËÁøÀÎÀÚ
  • safety factor
    ¾ÈÀü°è¼ö
  • virulence factor
    µ¶¼ºÀÎÀÚ, ¹ßº´ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • colonization factor
    Áý¶ôÇü¼ºÀÎÀÚ, ¼¼Æ÷±ºÇü¼ºÀÎÀÚ
  • colonizing factor antigen (CFA)
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • colony stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ(ó¢Õªí©Ð½ì×í­)
  • colony stimulating factor 1 (CSF-1)
    Áý¶ôÀÚ±ØÀÎÀÚ-1, ¼¼Æ÷±ºÀÚ±ØÀÎÀÚ-1
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ(Íì÷×ì×í­).
  • competence factor
    Àû°Ý¼ºÀÎÀÚ
  • competence inducing factor
    Àû°ÝÀ¯¹ßÀÎÀÚ(îêÌ«ë¯Û¡ì×í­).
  • complementary factor
    º¸ÃæÀÎÀÚ(¡­ì×í­), º¸Ã¼ÀÎÀÚ.
  • conglutinogen activating factor
    ±³Âø¿ø (conglutinogen, factor IÀÇ ¿¾¸»)
  • conversion factor
    º¯È¯ ÀÎÀÚ
  • cooperative factor
    Çùµ¿ÀÎÀÚ.
  • cord factor
    ±Õ»öÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • transfer factor
    "ÀüÀÌ(ï®ì¹) ÀÎÀÚ(ì×í­), Àü´ÞÀÎÀÚ(îîÓ¹ì×í­)"
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • translocation factor
    ÀüÀ§ ÀÎÀÚ(ï®êÈì×í­)
  • TR factor
    TR ÀÎÀÚ(ì×í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • two-factor cross
    ÀÌÀÎÀÚ ±³Â÷(ì£ì×í­Îßó©)
  • van't Hoff factor
    ¹ÝÆ® È£ÇÁ ÀÎÀÚ(ì×í­)
  • von Willebrand factor
    Æù ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
  • Willebrand factor
    ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
  • xathine oxidase factor
    À鯾 ¿Á½Ãµ¥À̽º ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
DVI deep venous insufficiency; diastolic velocity integral; digital vascular imaging; Doppler velocity i...
DVIS digital vascular imaging system
DVR digital vascular reactivity; Doctor of Veterinary Radiology; double valve replacement; double ventri...
FVR feline viral rhinotracheitis; forearm vascular resistance
HPVD hypertensive pulmonary vascular disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
S-V Stromal-vascular
SVR Systemic Vascular Resistance
SVRI Systemic Vascular Resistance Index
SVRI Systemic vascular resistance
TPR Total peripheral vascular resistance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • tumor necrosis factor
    Á¾¾ç ±«»ç ÀÎÀÚ
    TNF. Á¾¾ç¿¡ °ü°èÇϰí ÀÖ´Â ¸é¿ª°èÀÇ ¼¼Æ÷ÀÎ Á¾¾ç ħÀ±¼º ¸²ÇÁ±¸
  • tumor necrotizing factor
    Á¾¾ç ±«»ç ÀÎÀÚ
  • turbo factor
    Åͺ¸ ÀÎÀÚ
  • V-factor
    V-ÀÎÀÚ
    Ç캸Çʷ罺¼ÓÀÇ ±ÕÀÇ ÀÌ¿­¼º ÀÎÀÚ.
  • variable factor
    °¡º¯ ÀÎÀÚ
  • Ven blood factor
    Ææ Ç÷¾× ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
  • vitamin B12-intrinsic factor
    ºñŸ¹Î B12-³»Àμº ÀÎÀÚ
  • wall correction factor
    º®±³Á¤ °è¼ö
  • wedge factor
    ½û±â ÀÎÀÚ
  • weighting factor
    °¡Áß°è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
citrovorum factor N5Formyl-5,6,7,8-tetrahydrofolic acid;the active form of folic acid which acts as a formyl group carrier in transformylation reactions; the calcium salt, leucovorin calcium, has therapeutic use.
Synonym: citrovorum factor, leucovorin.
(05 Mar 2000)
milk factor Member of the retrovirus subfamily Oncornavirinae, antigenically distinct from the murine leukaemia-sarcoma complex, that is associated with adenocarcinomatous tumours of the mammary gland, commonly latent in wild and laboratory mice and causing cancer only in genetically susceptible strains under certain hormonal influences.
Synonym: Bittner agent, Bittner virus, Bittner's milk factor, mammary cancer virus of mice, milk factor, mouse mammary tumour virus.
(05 Mar 2000)
clotting factor <haematology> A group of chemical constituents of the blood (factors I to XIII) which interact to make the blood clot.
(13 Nov 1997)
coagulation factor <haematology> Group of plasma protein substances (Factor I-XIII) contained in the plasma, which act in concert to bring about blood coagulation. Many of the factors contain EGF like domains.
(29 Sep 1997)
coagulation factor XI <haematology> A plasma serine protease with an apple domain.
(18 Nov 1997)
cobra venom factor A component of cobra venom that renders C3 proactivator (properdin factor B) susceptible to factor D of the properdin system, leading to activation of C3 and other components of complement and lysis of unsensitised erythrocytes.
(05 Mar 2000)
coenzyme factor <enzyme> An enzyme oxidizing dihydrolipoamide at the expense of NAD+; completes the oxidative decarboxylation of pyruvate; a part of several enzyme complexes (e.g., alpha-ketoglutarate dehydrogenase complex). Decreased activity leads to neuronal loss in brain resulting in psychomotor retardation.
Synonym: coenzyme factor, lipoamide dehydrogenase, lipoamide reductase (NADH), lipoyl dehydrogenase.
(05 Mar 2000)
monocyte chemotactic and activating factor Cytokine of the C C subfamily, co induced with IL-8 on stimulation of endothelial cells, fibroblasts or monocytes that activates and is chemotactic for, monocytes. A chemokine.
(18 Nov 1997)
monocyte derived neutrophil chemotactic factor <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
colony-stimulating factor <cell biology> A glycoprotein growth factor that regulates the differentiation of particular cells.
These substances act in either paracrine or autocrine fashion on marrow cells, appear to act synergistically and can exert actions on several lines of progenitor cells, and influence end cell function. These lymphokines induce the maturation and proliferation of white blood cells from the primitive cell types present in bone marrow such as the leucocyte, macrophage and monocyte lines.
These substances can also be made by recombinant DNA technology for use clinically to speed bone marrow recovery typically following chemotherapy.
Acronym: CSF
(18 Jul 2002)
W factor <biochemistry> A prosthetic group for carboxylase enzymes. Important in fatty acid biosynthesis and catabolism and has found widespread use as a covalent label for macromolecules which may then be detected by high affinity binding of labelled avidin or streptavidin. Essential growth factor for many cells.
(18 Nov 1997)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement chemotactic factor The activated complex of the fifth, sixth, and seventh components of complement (C567) which induces chemotaxis in the case of polymorphonuclear leukocytes.
(05 Mar 2000)
complement factor h <chemical> A beta-globulin that binds to complement 3b and makes ic3b (inactivated complement 3b) susceptible to cleavage by complement factor I. Complement factor h also acts as an alternative pathway complement inhibitor by interfering with the binding of properdin factor b to c3b.
Chemical name: Complement factor H
(12 Dec 1998)
complement factor I <enzyme> Serine proteinase that acts on ic3b (inactivated complement 3b) to cleave it into c3c and c3dg with the help of a trypsin-like proteolytic enzyme. Complement factor I was formerly called kaf, c3binf, or enzyme 3b inactivator.
Registry number: EC 3.4.21.45
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á